Belimumab (Benlysta) is a fully-humanized monoclonal antibody that inhibits B-lymphocyte stimulator (also known as B cell activating factor) and was approved by the U.S. Federal Drug Administration and European Medicines Evaluation Agency for treatment in adults with autoantibody-positive systemic lupus erythematosus (SLE). Rituximab (Rituxan) is a chimeric anti-CD20 monoclonal antibody targeting B lymphocytes. This review discusses the key findings of the phase III trials in adults with SLE and of real-world use of belimumab and rituximab in the care of both adult and pediatric SLE patients. It highlights the safety profile of belimumab and rituximab and gives insight into the consideration of these therapies for specific SLE disease states. It concludes with a discussion of the current clinical trials investigating B cell therapies in specific SLE disease states and a look to the future, with ongoing clinical trials.
RahmanAIsenbergDA. Systemic lupus erythematosus. N Engl J Med2008; 358: 929–939.
4.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
5.
PetriMOrbaiAMAlarconGS. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012; 64: 2677–2686.
6.
CostenbaderKHFeskanichDStampferMJKarlsonEW. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum2007; 56: 1251–1262.
7.
SymmonsDP. Frequency of lupus in people of African origin. Lupus1995; 4: 176–178.
8.
AskanaseADWallaceDJWeismanMH. Use of pharmacogenetics, enzymatic phenotyping and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus. J Rheumatol2009; 36: 89–95.
9.
CarneiroJRSatoEI. Double blind, randomized, placebo-controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol1999; 26: 1275–1279.
10.
UrowitzMBGladmanDDIbanezD. Evolution of disease burden over five years in a multi-center inception systemic lupus erythematosus cohort. Arthritis Care Res2012; 64: 132–137.
11.
BlumlSMckeeverKEttingerRSmolenJHerbstR. B cell targeted therapeutics in clinical development. Arthritis Res Ther2013; 15: S4–S4.
12.
KamalAKhamashtaM. The efficacy of novel B cell biologics as the future of SLE treatment: A review. Autoimmun Rev2014; 13: 1094–1101.
13.
NashiEWangYDiamondB. The role of B cells in lupus pathogenesis. J Biochem Cell Biol2010; 42: 543–550.
14.
VincentFBMorandEFSchneiderRMackayF. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol2014; 10: 365–373.
15.
ZhangJRoschkeVBakerKP. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol2001; 16: 6–10.
16.
RitterhouseLLCroweSRNiewoldTB. B lymphocyte stimulator levels in systemic lupus erythematosus: Higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels. Arthritis Rheum2011; 63: 3931–3941.
17.
PetriMStohlWChathamW. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum2008; 58: 2453–2459.
18.
YazdanyJErkanDSanchez-GuerreroJ. Post-marketing experience with belimumab in US Lupus centers: Data from the Lupus Clinical Trials Consortium, Inc (LCTC) national patient registry (abstract). Arthritis Rheum2013; 65: 1605–1605.
19.
AskanaseADYazdanyJMoltaCT. Post-marketing experiences of belimumab in the treatment of SLE patients. Rheum Dis Clin North Am2014; 40: 501–517.
20.
Hui-YuenJSReddyATaylorJ. Safety and efficacy of belimumab to treatment systemic lupus erythematosus in academic clinical practices. J Rheumatol2015; 42: 2288–2295.
21.
CollinsCEDall’EraMKanH. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBServe study in the USA. Lupus Sci Med2016; 3: e000118–e000118. Doi:10.1136/lupus-2015-000118.
22.
NavarraSVGuzmanRMGallacherAE. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomized, placebo-controlled phase 3 trial. Lancet2011; 377: 721–731.
23.
FurieRPetriMAZamaniO. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum2011; 63: 3918–3930.
24.
Van VollenhovenRFPetriMACerveraR. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis2012; 71: 1343–1349.
25.
DooleyMAHoussiauFAranowC. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus2013; 22: 63–72.
26.
StohlWSchwartingAOkadaM. A randomized, double-blind, placebo-controlled, 52-week study of the efficacy and safety of belimumab administered subcutaneously plus standard care to patients with systemic lupus erythematosus (SLE) [abstract]. Arthritis Rheumatol2015; 67(suppl 10).
27.
FurerVZismanDPokroy-ShapiraEMoladYElkayamOParanD. Systemic lupus erythematosus exacerbation following cessation of belimumab treatment. Scand J Rheumatol2016; 45: 103–106.
28.
MerrillJTvan VollenhovenRFBuyonJP. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicenter, randomized, double-blind, placebo-controlled study. Ann Rheum Dis2016; 75: 332–340.
29.
IsenbergDAPetriMKalunianK. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicenter, randomized, double-blind, placebo-controlled study. Ann Rheum Dis2016; 75: 323–331.
30.
StohlWMerrillJTLooneyRJ. Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and 1b trials. Arthritis Res Ther2015; 17: 215–215.
31.
GinzlerEMWallaceDJMerrillJT. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol2014; 41: 300–309.
32.
WallaceDJNavarraSVPetriMA. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus2013; 22: 144–154.
33.
BruceINUrowitzMvan VollenhovenR. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus2016; 25: 699–709.
34.
FredericksCKvamKBearJCrabtreeGJosephsonS. A case of progressive multifocal leukoencephalopathy in a lupus patients treated with belimumab. Lupus2014; 23: 311–313.
35.
BernatskySBoivinJFJosephL. Mortality in systemic lupus erythematosus. Arthritis Rheum2006; 54: 2550–2557.
36.
GalarzaCValenciaDTobonGJ. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?Clin Rev Allergy Immunol2008; 34: 124–128.
37.
JonsdottirTGunnarssonIRisseladaAHenrikssonEWKlareskogLvan VollenhovenRF. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis2008; 67: 330–334.
38.
LeandroMJEdwardsJCCambrigeGEhrensteinMRIsenbergDA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum2002; 46: 2673–2677.
39.
LeandroMJCambridgeGEdwardsJCEhrensteinMRIsenbergDA. B cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatol2005; 44: 1542–1545.
40.
Van VollenhovenRFGunnarssonIWelin-HenrikssonE. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand J Rheumatol2004; 33: 423–427.
41.
CambridgeGLeandroMJTeodorescuM. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum2006; 54: 3612–3622.
42.
SmithKGJonesRBBurnsSMJayneDR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum2006; 54: 2970–2982.
43.
TokunagaMSaitoKKawabataD. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis2007; 66: 470–475.
44.
MerrillJTNeuweltCMWallaceDJ. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial (EXPLORER). Arthritis Rheum2010; 62: 222–233.
45.
RovinBFurieRLatinisK. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study (LUNAR). Arthritis Rheum2012; 64: 1215–1226.
46.
Cobo-IbanezTLoza-SantamariaEPeg-ReigosaJM. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum2014; 44: 175–185.
47.
LindholmCBorjesson-AspKZendjanchiK. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol2008; 35: 826–833.
48.
AlbertDDunhamJKhanS. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythematosus. Ann Rheum Dis2008; 67: 1724–1731.
49.
TerrierBAmouraZRavaudP. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French Autoimmunity and Rituximab registry. Arthritis Rheum2010; 62: 2458–2466.
50.
Ramos-CasalsMGarcia-HernandezFJde RamonE. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol2010; 28: 468–476.
51.
VitalEMDassSBuchMH. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum2011; 63: 3038–3047.
52.
Fernandez-NebroAde la FuenteJLCarrenoL. Multicenter longitudinal study of B lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. Lupus2012; 21: 1063–1076.
53.
PintoLFVelasquezCJPrietoC. Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus. Lupus2011; 20: 1219–1226.
54.
NarvaezJRios-RodriguezVde la FuenteD. Rituximab therapy in refractory neuropsychiatric lupus: Current clinical evidence. Semin Arthritis Rheum2011; 41: 364–372.
55.
HortonHMChuSYOrtizEC. Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral responses in systemic lupus erythematosus. J Immunol2011; 186: 4223–4233.
56.
LeadbetterEARifkinIRHolhbaumAM. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature2002; 416: 603–607.
57.
OtipobyKLAnderssonKBDravesKE. CD22 regulates thymus-independent responses and the lifespan of B cells. Nature1996; 384: 634–637.
58.
DornerTKaufmannJWegenerWA. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther2006; 8: R74–R74.
59.
WallaceDJGordonCStrandV. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicenter studies (ALLEVIATE) and follow-up. Rheumatology (Oxford)2013; 52: 1313–1322.
TambralliABeukelmanTCronRQStollML. Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases. J Rheumatol2015; 42: 541–546.
62.
OlfatMSilvermanEDLevyDM. Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus. Lupus2015; 24: 966–972.
63.
DaleRCBrilotFDuffyLV. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology2014; 83: 142–150.
64.
LehmanTJSinghCRamanathanA. Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Pediatr Rheumatol2014; 12: 3–3.
65.
HenegarCEEudyAMKharatVHillDDBennettDHaightB. Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review. Lupus2016; 25: 617–626.
66.
CondonMBAshbyDPepperRJ. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis2013; 72: 1280–1286.
67.
EhrensteinMRWingC. The BAFFling effects of rituximab in lupus: danger ahead?Nat Rev Rheumatol2016; 12: 367–372.
